BG
SUPN icon

Bellevue Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Bellevue Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,100
Closed -$437K – 177
2023
Q4 		$437K Sell
15,100
-565,500
-97% -$15M 0.01% 136
2023
Q3 		$16M Sell
580,600
-69,656
-11% -$2.12M 0.26% 77
2023
Q2 		$19.5M Buy
650,256
+527,375
+429% +$18.5M 0.28% 80
2023
Q1 		$4.45M Buy
122,881
+11,835
+11% +$455K 0.06% 107
2022
Q4 		$3.96M Sell
111,046
-8,232
-7% -$286K 0.05% 114
2022
Q3 		$4.04M Buy
119,278
+36,878
+45% +$1.2M 0.06% 112
2022
Q2 		$2.38M Buy
82,400
+23,400
+40% +$670K 0.03% 125
2022
Q1 		$1.91M Buy
+59,000
New +$1.81M 0.02% 136
2020
Q2 		– Sell
-552,800
Closed -$9.95M – 224
2020
Q1 		$9.95M Sell
552,800
-22,800
-4% -$479K 0.19% 88
2019
Q4 		$13.7M Buy
575,600
+159,000
+38% +$3.86M 0.22% 78
2019
Q3 		$11.4M Sell
416,600
-50,400
-11% -$1.49M 0.21% 80
2019
Q2 		$15.5M Buy
467,000
+176,000
+60% +$6.03M 0.26% 66
2019
Q1 		$10.2M Sell
291,000
-54,100
-16% -$2.01M 0.56% 53
2018
Q4 		$11.5M Sell
345,100
-41,400
-11% -$1.78M 0.75% 41
2018
Q3 		$19.5M Buy
386,500
+59,900
+18% +$2.96M 1.23% 24
2018
Q2 		$19.5M Buy
326,600
+37,800
+13% +$1.96M 1.67% 21
2018
Q1 		$13.2M Buy
288,800
+48,400
+20% +$2.02M 1.31% 27
2017
Q4 		$9.58M Buy
+240,400
New +$9.5M 1% 40
2016
Q3 		– Sell
-164,000
Closed -$3.34M – 124
2016
Q2 		$3.34M Sell
164,000
-277,000
-63% -$4.91M 0.63% 51
2016
Q1 		$6.72M Buy
+441,000
New +$5.75M 1.22% 24

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Bellevue Group's SUPN Position: Q1 2024 in Review

Bellevue Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2024, closing a stake of 15,100 shares — an estimated $437K sold.

Bellevue Group first reported a position in SUPN in Q1 2016 and held it in 20 quarters. The position peaked at $19.5M in Q2 2018. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

  • Bellevue Group reported no remaining Supernus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Bellevue Group sold 15,100 Supernus Pharmaceuticals shares in Q1 2024, an estimated $437K.
  • Bellevue Group first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 20 quarters.
  • Bellevue Group's Supernus Pharmaceuticals position peaked at $19.5M in Q2 2018.
  • 250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.